119 related articles for article (PubMed ID: 27069174)
1. Prognostic Significance of a Minute Amount of Ascites During Chemoradiotherapy for Locally Advanced Pancreatic Cancer.
Shinoto M; Nakamura K; Shioyama Y; Sasaki T; Nishie A; Asayama Y; Ohga S; Yoshitake T; Terashima K; Asai K; Matsumoto K; Honda H
Anticancer Res; 2016 Apr; 36(4):1879-84. PubMed ID: 27069174
[TBL] [Abstract][Full Text] [Related]
2. Gemcitabine and S-1 Induction Chemotherapy Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancers.
Maemura K; Mataki Y; Kurahara H; Kawasaki Y; Iino S; Sakoda M; Uchikado Y; Arigami T; Uenosono Y; Mori S; Ueno S; Shinchi H; Natsugoe S
Anticancer Res; 2017 Jan; 37(1):233-237. PubMed ID: 28011497
[TBL] [Abstract][Full Text] [Related]
3. Salvage chemoradiotherapy after primary chemotherapy for locally advanced pancreatic cancer: a single-institution retrospective analysis.
Mayahara H; Ito Y; Morizane C; Ueno H; Okusaka T; Kondo S; Murakami N; Morota M; Sumi M; Itami J
BMC Cancer; 2012 Dec; 12():609. PubMed ID: 23256481
[TBL] [Abstract][Full Text] [Related]
4. Prognostic factor analysis of irreversible electroporation for locally advanced pancreatic cancer - A multi-institutional clinical study in Asia.
Yang PC; Huang KW; Pua U; Kim MD; Li SP; Li XY; Liang PC
Eur J Surg Oncol; 2020 May; 46(5):811-817. PubMed ID: 31839436
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of induction gemcitabine and S-1 followed by chemoradiotherapy and systemic chemotherapy using S-1 for locally advanced pancreatic cancer.
Sudo K; Hara R; Nakamura K; Kita E; Tsujimoto A; Yamaguchi T
Cancer Chemother Pharmacol; 2017 Jul; 80(1):195-202. PubMed ID: 28597040
[TBL] [Abstract][Full Text] [Related]
6. Prognostic factors for survival and resection in patients with initial nonresectable locally advanced pancreatic cancer treated with chemoradiotherapy.
Bjerregaard JK; Mortensen MB; Jensen HA; Nielsen M; Pfeiffer P
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(3):909-15. PubMed ID: 22172900
[TBL] [Abstract][Full Text] [Related]
7. [A case of locally advanced pancreas cancer effectively treated by multidisciplinary strategy].
Hasegawa K; Katsuta E; Iwata N; Aoyagi H; Yoshida T; Takahata T; Kaneko J; Maejima S
Gan To Kagaku Ryoho; 2011 Nov; 38(12):2152-4. PubMed ID: 22202313
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of carbohydrate antigen 19-9 in unresectable locally advanced pancreatic cancer treated with dose-escalated intensity modulated radiation therapy and concurrent full-dose gemcitabine: analysis of a prospective phase 1/2 dose escalation study.
Vainshtein JM; Schipper M; Zalupski MM; Lawrence TS; Abrams R; Francis IR; Khan G; Leslie W; Ben-Josef E
Int J Radiat Oncol Biol Phys; 2013 May; 86(1):96-101. PubMed ID: 23265573
[TBL] [Abstract][Full Text] [Related]
9. miR-21 expression and clinical outcome in locally advanced pancreatic cancer: exploratory analysis of the pancreatic cancer Erbitux, radiotherapy and UFT (PERU) trial.
Khan K; Cunningham D; Peckitt C; Barton S; Tait D; Hawkins M; Watkins D; Starling N; Rao S; Begum R; Thomas J; Oates J; Guzzardo V; Fassan M; Braconi C; Chau I
Oncotarget; 2016 Mar; 7(11):12672-81. PubMed ID: 26862857
[TBL] [Abstract][Full Text] [Related]
10. Prognostic factors in patients with advanced pancreatic cancer treated with gemcitabine alone or gemcitabine plus cisplatin: retrospective analysis of a multicenter study.
Inal A; Kos FT; Algin E; Yildiz R; Berk V; Tugba Unek I; Colak D; Colak D; Kucukoner M; Tamer Elkiran E; Helvaci K; Geredeli C; Dane F; Balakan O; Ali Kaplan M; Gok Durnali A; Harputoglu H; Goksel G; Ozdemir N; Buyukberber S; Gumus M; Ozkan M; Benekli M; Isikdogan A;
J BUON; 2012; 17(1):102-5. PubMed ID: 22517701
[TBL] [Abstract][Full Text] [Related]
11. High-dose helical tomotherapy with concurrent full-dose chemotherapy for locally advanced pancreatic cancer.
Chang JS; Wang ML; Koom WS; Yoon HI; Chung Y; Song SY; Seong J
Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):1448-54. PubMed ID: 22285669
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of volume-based FDG PET/CT parameters in patients with locally advanced pancreatic cancer treated with chemoradiation therapy.
Choi HJ; Lee JW; Kang B; Song SY; Lee JD; Lee JH
Yonsei Med J; 2014 Nov; 55(6):1498-506. PubMed ID: 25323885
[TBL] [Abstract][Full Text] [Related]
13. Intravenous and intraperitoneal paclitaxel with S-1 for treatment of refractory pancreatic cancer with malignant ascites.
Takahara N; Isayama H; Nakai Y; Ishigami H; Satoi S; Mizuno S; Kogure H; Matsubara S; Yamamoto N; Yamaguchi H; Tada M; Kitayama J; Watanabe T; Koike K
Invest New Drugs; 2016 Oct; 34(5):636-42. PubMed ID: 27339809
[TBL] [Abstract][Full Text] [Related]
14. Concurrent chemoradiotherapy with or without induction chemotherapy versus chemotherapy alone in patients with locally advanced pancreatic cancer.
Huang WK; Kuo YC; Tsang NM; Hsu HC; Shen WC; Chou WC; Yang TS; Chen JS
Anticancer Res; 2014 Nov; 34(11):6755-61. PubMed ID: 25368287
[TBL] [Abstract][Full Text] [Related]
15. [A case of advanced pancreatic cancer successfully treated by combined chemotherapy of S-1 and gemcitabine].
Kawasaki H; Kukita K; Mizushima Y; Hirata K
Gan To Kagaku Ryoho; 2008 Jul; 35(7):1239-42. PubMed ID: 18633272
[TBL] [Abstract][Full Text] [Related]
16. S-1 plus gemcitabine chemotherapy followed by concurrent radiotherapy and maintenance therapy with S-1 for unresectable pancreatic cancer.
Ke QH; Zhou SQ; Yang JY; Du W; Liang G; Lei Y; Luo F
World J Gastroenterol; 2014 Oct; 20(38):13987-92. PubMed ID: 25320537
[TBL] [Abstract][Full Text] [Related]
17. A nomogram for predicting survival of patients with locally advanced pancreatic cancer treated with chemoradiotherapy.
Choi SH; Park SW; Seong J
Radiother Oncol; 2018 Nov; 129(2):340-346. PubMed ID: 30177371
[TBL] [Abstract][Full Text] [Related]
18. Gemcitabine and S-1 versus gemcitabine and cisplatin treatment in patients with advanced biliary tract cancer: a multicenter retrospective study.
Takahara N; Isayama H; Nakai Y; Sasaki T; Ishigaki K; Saito K; Akiyama D; Uchino R; Mizuno S; Yagioka H; Kogure H; Togawa O; Matsubara S; Ito Y; Toda N; Tada M; Koike K
Invest New Drugs; 2017 Jun; 35(3):269-276. PubMed ID: 28124197
[TBL] [Abstract][Full Text] [Related]
19. Clinical implications of the serum CA19-9 level in "biological borderline resectability" and "biological downstaging" in the setting of preoperative chemoradiation therapy for pancreatic cancer.
Takahashi H; Yamada D; Asukai K; Wada H; Hasegawa S; Hara H; Shinno N; Ushigome H; Haraguchi N; Sugimura K; Yamamoto K; Nishimura J; Yasui M; Omori T; Miyata H; Ohue M; Yano M; Sakon M; Ishikawa O
Pancreatology; 2020 Jul; 20(5):919-928. PubMed ID: 32563596
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of serum CA19-9 in patients with advanced pancreatic cancer receiving gemcitabine based chemotherapy.
An X; Li YH; Lin XB; Wang FH; Feng F; Xu RH; Jiang WQ; He YJ
Ai Zheng; 2009 Mar; 28(3):286-91. PubMed ID: 19619444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
